Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Omega-3-Acid Triglycerides→

Omega-3-Acid Triglycerides Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
329042-31-1
Molecular formula
C60H92O6
Molecular weight
909.4 g/mol
Drug class
Omega-3 polyunsaturated fatty-acid mixturetriglyceride-lowering lipid-modifying agent
Mechanism of action
The precise mechanism depends on the formulation. EPA and DHA can reduce hepatic triglyceride synthesis through reduced diacylglycerol acyltransferase activity, increased mitochondrial and peroxisomal beta-oxidation, decreased hepatic lipogenesis and increased plasma lipoprotein-lipase activity.
Indications / reported uses
  • Omega-3 fatty-acid prescription products are used as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridaemia when the specific EPA/DHA formulation and product label support this indication. Do not generalise prescription indications to all fish-oil or dietary-supplement products.

Sources: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e40d55f2-db9f-4a48-8639-9aa7491e4de5&type=display · https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5fe15bdb-f59f-4b87-8e5d-8a3d5683eb3d&type=display · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Omega-3 polyunsaturated fatty-acid mixture; triglyceride-lowering lipid-modifying agent

Mechanism of action

The precise mechanism depends on the formulation. EPA and DHA can reduce hepatic triglyceride synthesis through reduced diacylglycerol acyltransferase activity, increased mitochondrial and peroxisomal beta-oxidation, decreased hepatic lipogenesis and increased plasma lipoprotein-lipase activity.

General use cases

  • Omega-3 fatty-acid prescription products are used as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridaemia when the specific EPA/DHA formulation and product label support this indication. Do not generalise prescription indications to all fish-oil or dietary-supplement products.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Omega-3-Acid Triglycerides Environmental Risk Assessment (ERA) (the Omega-3-Acid Triglycerides ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.